ARS Pharmaceuticals, Inc. (SPRY)

$5.55

USD

+0.19(3.54%)

At close: Aug 06, 17:05 EDT

Recently from Cashu

Challenges Ahead for ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. (SPRY) is facing significant challenges as it navigates the complexities of the pharmaceutical market, particularly surrounding its leading product, neffy® (epinephrine nasal…

Cashu Markets·1h ago

ARS Pharmaceuticals Faces Major Setback

ARS Pharmaceuticals, Inc. ( SPRY ) has encountered significant challenges in recent weeks, highlighting the complexities of launching innovative pharmaceutical products in a competitive market. The co…

Cashu Markets·1 month ago

Open

$8.60

Prev. Close

$5.46

High

$8.62

Low

$8.18

Company Profile

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

CEODonn Casale

SectorHealthcare

IndustryBiotechnology

Employees163

IPO DateDec 4, 2020

ExchangeNASDAQ

Exchange NameNASDAQ Global Market

CurrencyUSD

Headquarters & Contact

Address11682 El Camino Real

City / State / ZIPSan Diego, CA, 92130

CountryUnited States

Phone858 335 1300

Websitehttps://ars-pharma.com